POLYDORM

Uncovering the molecular and cellular mechanism of tumor dormancy for the rational design of theranostic nanomedicines

 Coordinatore TEL AVIV UNIVERSITY 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Israel [IL]
 Totale costo 2˙255˙920 €
 EC contributo 2˙255˙920 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2013-CoG
 Funding Scheme ERC-CG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-04-01   -   2019-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Ms.
Nome: Lea
Cognome: Pais
Email: send email
Telefono: +972 36408774
Fax: +972 36409697

IL (TEL AVIV) hostInstitution 2˙255˙920.00
2    TEL AVIV UNIVERSITY

 Organization address address: RAMAT AVIV
city: TEL AVIV
postcode: 69978

contact info
Titolo: Prof.
Nome: Ronit
Cognome: Satchi-Fainaro
Email: send email
Telefono: +972 36409113
Fax: +972 36407427

IL (TEL AVIV) hostInstitution 2˙255˙920.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

dormancy    dormant    cancer    disease    interactions    cells    biology    fundamental    molecular    progression    fast    tumor    phenomenon    clinical    polymer    dependent    tumors   

 Obiettivo del progetto (Objective)

'Tumor progression is dependent on a number of sequential steps, including initial tumor-vascular interactions and recruitment of blood vessels, as well as an established interaction of tumor cells with their surrounding microenvironment. Failure of a microscopic tumor, either primary, recurrent or metastatic, to complete one or more of these early stages may lead to delayed clinical manifestation of the cancer and a state of stable non-progressing disease. Micrometastasis, dormant tumors, and residual tumor cells contribute to the occurrence of relapse, and constitute fundamental clinical manifestations of tumor dormancy that together are responsible for the vast majority of cancer deaths. However, although the tumor dormancy phenomenon has critical implications for early detection and treatment of cancer, its biology and genetic characteristics are poorly understood. We now propose to investigate the molecular and cellular changes in tumor-host interactions that govern tumor dormancy, which may lead to the discovery of novel tumor dormancy targets and provide tools for dormancy-dependent tumor therapy strategies. In order to achieve this goal, we will integrate the following basic and translational approaches: (i) Establishment of mouse models of dormant and fast-growing tumor pairs; (ii) Functional and molecular characterization of dormant versus fast-growing tumors, (iii) Design of dormancy-promoting tailor-made polymer therapeutics delivering a combination of microRNAs with chemotherapies; (iv) Polymer conjugation to a prodrug designed to be activated by specific enzymes overexpressed in tumors, Turning-ON a near infra-red (NIR) fluorescence signal. When completed, this proposal will shed light on this fundamental cancer biology phenomenon. A better understanding of tumor dormancy and the availability of markers and therapeutic targets will most likely change our perception of tumor progression and, consequently, the way we diagnose and treat the disease.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

MEME (2012)

Membrane-modified Electrodes to study Membrane Enzymes

Read More  

BIOSMA (2008)

Mathematics for Shape Memory Technologies in Biomechanics

Read More  

STARKEY (2014)

Solving the TP-AGB STAR Conundrum: a KEY to Galaxy Evolution

Read More